Novel radioligands to improve radiotherapy of NETs
Researcher: Kuo-Shyan Lin, PhD Location: BC Cancer State: Outside of the U.S. Year: 2018 Status: Active Grant Duration: 1 year Award: Pilot Award
Leave it blank
Scientists will explore a novel, very stable compound that binds to NET cells’ somatostatin receptors (SSTR2) more tightly than lutetium 177 (Lu-177) dotatate. This new radiopharmaceutical will be compared with Lu-177 dotatate in disease models. Researchers hope tighter binding of this radiotherapeutic agent to cancer cell receptors will lead to higher radiation accumulation and improved cancer response.
NET Research Foundation
321 Columbus Avenue, Suite 5R
Boston MA 02116